SCHEDULE: HRT Financial LP Reports Stake in bioAffinity Technologies
Schedule 13G Filing
HRT Financial LP has disclosed beneficial ownership of 10.9% of bioAffinity Technologies' common stock as of September 30, 2026.
Summary
- HRT Financial LP has filed a Schedule 13G, indicating it beneficially owns 127,132 shares of bioAffinity Technologies, Inc. common stock.
- This ownership represents 10.9% of the outstanding shares as of September 30, 2026.
- The reported shares include 126,146 shares held directly and 986 shares issuable upon the exercise of warrants.
- The filing is made under Rule 13d-1(b), indicating HRT Financial LP is a broker or dealer registered under section 15 of the Act.
- The certification confirms these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new financial or strategic information.
Positives
- HRT Financial LP's investment indicates confidence in bioAffinity Technologies, potentially signaling market interest.
- The disclosure provides transparency regarding a significant shareholder's holdings.
Negatives
- The filing does not provide new financial performance data or strategic updates for bioAffinity Technologies.
- The increase in stake by a financial entity could be interpreted as a precursor to activist involvement, though not explicitly stated.
Risks
- Potential for increased market volatility if HRT Financial LP's trading activity is significant.
- The filing does not detail the specific strategy or intent behind HRT Financial LP's investment, leaving room for speculation.
Future Outlook
The filing itself does not contain forward-looking statements or guidance from bioAffinity Technologies. It solely reports on the ownership stake of HRT Financial LP.
Management Comments
- HRT Financial LP certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and hedge funds acquiring significant stakes. This filing places bioAffinity Technologies within the context of companies attracting institutional investment, though the specific strategic implications for the company are not detailed in this document.
Stakeholder Impact
- Shareholders: Increased institutional ownership may lead to greater market liquidity and potentially influence stock price, but also introduces a large holder whose future actions are not detailed.
- Creditors: No direct impact indicated by this filing.
- Employees: No direct impact indicated by this filing.
- Customers/Suppliers: No direct impact indicated by this filing.
Next Steps
- HRT Financial LP will continue to hold its shares in bioAffinity Technologies, subject to its ordinary course of business practices.
- bioAffinity Technologies, Inc. will continue its operations as previously disclosed.
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Date of Event Which Requires Filing of this Statement (Ownership as of this date) |
| 2026-11-06 | Date bioAffinity Technologies, Inc. filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 |
| 2026-11-19 | Date of Signature on Schedule 13G filing |
Keywords
Schedule 13G, Beneficial Ownership, bioAffinity Technologies, HRT Financial LP, Common Stock, Warrants, SEC Filing, Shareholder
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.